新闻BenzingaLiquidia Will Continue To Advance YUTREPIA And L606 Clinical Programs As Previously Outlined; Liquidia Has Submitted A Supplement To Remove The PH-ILD Indication From YUTREPIA’ ’s Label And No Longer Promotes It For PH-ILD Liquidia Will Continue To Advance YUTREPIA And L606 Clinical Programs As Previously Outlined; Liquidia Has Submitted A Supplement To Remove The PH-ILD Indication From YUTREPIA’ ’s Label And No Longer Promotes It For PH-ILD Benzinga 2026.10.13 21:52 (GMT+0) 在Benzinga上打开 其他新闻 房屋建筑商信心跌至2012年以来低点，股市交易表现如同新冠疫情期间一样 FDA批准了GSK一款可能改变某些直肠癌治疗方式的药物 英伟达研究人员使用超级计算机 Jupiter 进行容错计算模拟 吉利德凭借有前景的中期试验成功加强炎症性肠病研发管线 SpaceX股票震荡：埃隆·马斯克的股票赠予遭遇内幕抛售 摩根士丹利维持对 Fractyl Health 的“与大盘持平”评级，将目标价下调至 4 美元
